Beam Therapeutics Inc. (BEAM) News
Filter BEAM News Items
BEAM News Results
|Loading, please wait...|
BEAM News Highlights
- 500 - Internal server error
- Over the past 18 days, the trend for BEAM's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- GENE, BIO and GHVI are the most mentioned tickers in articles about BEAM.
Latest BEAM News From Around the Web
Below are the latest news stories about Beam Therapeutics Inc that investors may wish to consider to help them evaluate BEAM as an investment opportunity.
Cryptos are one of the hottest investment trends right now, but not everyone makes the cut on the privacy end due to regulatory pressure.
In hindsight, the pandemic may have been that turning point for gene-based medicine. The authorization of the first vaccines using messenger RNA validated a segment of the life sciences industry that seemed destined for some futuristic version of healthcare. Genome sequencing and gene editing have been around for several years.
Photo by BlackJack3D/E+ via Getty Images Last time we saw, Beam Therapeutics (BEAM) was planning a "wave" of INDs beginning in 2021. Now that we are in the middle of 2021, we want to see what they have been up to. Beam Therapeutics, if you recall, is a $4.4bn recent...
Beam Therapeutics is pioneering the use of base editing - a potential new class of precision genetic medicines. This is way above my pay grade so let's look at the charts of BEAM. In this daily bar chart of BEAM, below, we can see that prices made a base in the $20-$30 area before rallying to a high in February above $120.
CAMBRIDGE, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will participate in a fireside chat during the 2021 Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 9:30 a.m. ET.
Bitcoin (CRYPTO: BTC) and Dogecoin (CRYPTO: DOGE) -- are down more than 40% from their highs set earlier this year. Here are three growth stocks to buy that could easily be bigger winners than Bitcoin and Dogecoin. Gores Holdings VI (NASDAQ: GHVI) shares are currently down more than 40% from the peak in February.
Prime Editing Technology Market to See Major Growth by 2026 : Horizon Discovery, Beam Therapeutics, Inscripta, Precision BioSciences
Edison, NJ -- ( SBWIRE ) -- 05/17/2021 -- A new research document released by HTF MI with title "Global Prime Editing Technology Market Trend Anslysis & Growth 2021-2026" provides a complete assessment of Prime Editing Technology Market. The study focuses on changing market dynamics, geopolitical and regulatory policies, key players Strategies to better analyse demand at risk across various product type. Some of the major and emerging players analysed in the study are Beam Therapeutics, Inscripta, Precision BioSciences, Sangamo Therapeutics, Horizon Discovery, CRISPR Therapeutics, GenScript, Intellia Therapeutics & Synthego Corporation etc. Access Sample Copy of Prime Editing Technology Market Report @: https://www.htfmarketreport.com/sample-report/3282709-global-prime-editing-technolog...
Shares of Beam Therapeutics Inc. (NASDAQ:BEAM) dropped 8.2% on Monday following a dissappointing earnings announcement. The stock traded as low as $64.69 and last traded at $64.99. Approximately 2,073 shares traded hands during mid-day trading, a decline of 100% from the average daily volume of 1,034,089 shares. The stock had previously closed at $70.82. The 
Beam Therapeutics Takes $155M In-Process R&D Expense Hit To Bottomline, But Receives Buy Rating From Redburn Partners
Beam Therapeutics Inc (NASDAQ: BEAM ) reported a wider Q1 net loss of $201.6 million compared to $31.7 million a year ago, on higher R&D costs of $190.1 million, up from $21.5 million in Q1 2020. It includes $155 million of expense related to in-process research and development acquired from Guide Therapeutics Inc in February this year. Beam ended Q1 with cash and equivalents of $503.5 million. The company also presented data at ASGCT on its proprietary lipid nanoparticle (LNP) formulation showing efficient in vivo base editing in hepatocytes of non-human primates (NHPs). Beam evaluated various LNP formulations and … Full story available on Benzinga.com
View more earnings on RCKTSee more from BenzingaClick here for options trades from BenzingaBeam Therapeutics Takes 5M In-Process R&D Expense Hit To Bottomline, But Receives Buy Rating From Redburn PartnersLilly, MiNA Ink Broad RNA Deal Worth .25B© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.